Drug Trial Radar · NCT05291091
Phase 2 Study of EDG-5506 in Becker Muscular Dystrophy (GRAND CANYON)
Last checked: Nov 19, 2026Latest source record: Sep 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
244
Actual
Start
Nov 10, 2022
Primary completion
Sep 7, 2026
Study completion Sep 7, 2026
Sponsor
- Lead sponsor
- Edgewise Therapeutics, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.; ImagingNMD; SYSNAV
- First posted
- Mar 22, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 12 years, up to 50 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of sevasemten (EDG-5506) in Becker muscular dystrophy (known as CANYON) and pivotal cohort (known as GRAND CANYON). The EDG-5506-201 CANYON study was expanded to include an additional 175 adult participants in a cohort called GRAND CANYON, that is a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of sevasemten in adults with Becker.
Conditions
- Becker Muscular Dystrophy
Interventions
Sevasemten 10 mgDrug
Sevasemten is administered orally once per day
Sevasemten 5 mgDrug
Sevasemten is administered orally once per day
Sevasemten 12.5 mgDrug
Sevasemten is administered orally once per day
PlaceboDrug
Placebo is administered orally once per day
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of treatment emergent adverse events in those treated with sevasemten or placeboTime frame: 12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
- Severity of treatment emergent adverse events in those treated with sevasemten or placeboTime frame: 12 months (CANYON Cohorts 1, 2, 4, 5), 18 months (GRAND CANYON Cohort 6)
- Change from Baseline in serum Creatine KinaseTime frame: Averaged across Months 6, 9, 12 Months (CANYON Cohorts 1, 2)
- Change from Baseline in total North Star Ambulatory Assessment scoreTime frame: 18 months (GRAND CANYON Cohort 6)
Locations
51 sites in 12 countries. Site status is shown where the registry gives one.
Arkansas Children's Hospital
Little Rock, Arkansas
UC San Diego
La Jolla, California
UCLA Medical Center
Los Angeles, California
UC Irvine Medical Center
Orange, California
Stanford Neuroscience Health Center
Palo Alto, California
UC Davis Medical Center
Sacramento, California
UC Denver
Aurora, Colorado
University of Florida
Gainesville, Florida
Rare Disease Research
Atlanta, Georgia
Northwestern University
Chicago, Illinois
Indiana University School of Medicine
Indianapolis, Indiana
University of Iowa
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Kennedy Krieger Institute
Baltimore, Maryland
University of Massachusetts Memorial Medical Center
Worcester, Massachusetts
University of Minnesota
Minneapolis, Minnesota
Washington University School of Medicine
St Louis, Missouri
University of Rochester Medical Center
Rochester, New York
Rare Disease Research, LLC NC
Hillsborough, North Carolina
University of Cincinnati Gardner Neuroscience Institute
Cincinnati, Ohio
Nationwide Children's Hospital
Columbus, Ohio
University of Pennsylvania
Philadelphia, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania
National Neuromuscular Research Institute
Austin, Texas
Neurology Rare Disease Center
Denton, Texas
Virginia Commonwealth University Health
Richmond, Virginia
St Vincent's Hospital Melbourne
Fitzroy, Australia
Universitaire Ziekenhuizen Leuven
Leuven, Belgium
Centre Hospitalier Régional de la Citadelle
Liège, Belgium
University Hospital Gent
Ghent, Belgium, Belgium
Rigshospitalet
Copenhagen, Denmark
Centre de Reference des Maladies Neuromusculaires et de la SLA - AP-HM Hopital de La Timone
Marseille, France
CHU de Nantes
Nantes, France
CHU de Nice - Hopital Pasteur 2 - Centre de reference des Maladies Neuromusculaires
Nice, France
AP-HP Hopital Pitie-Salpetriere
Paris, France
Klinikum der Ludwig-Maximilians-Universitaet Muenchen
Munich, Germany
Hadassah University Hospital
Jerusalem, Israel
Schneider Children's Hospital of Israel
Petah Tikva, Israel
Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano
Milan, Italy
Azienda Ospedale - Università Padova
Padova, Italy
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.